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Abstract
Traditionally, genetic testing has been too slow or perceived to be impractical to initial 
management of the critically ill neonate. Technological advances have led to the ability to 
sequence and interpret the entire genome of a neonate in less than 50 hours. As the cost and speed 
of testing decreases, the utility of whole genome sequencing (WGS) of neonates for acute and 
latent genetic illness increases. Analyzing the entire genome allows for concomitant evaluation of 
the currently identified 5,430 single gene diseases. When applied to a select population of ill 
infants in a level IV neonatal intensive care unit, WGS yielded a diagnosis of a causative genetic 
disease in 57% of patients. These diagnoses may lead to clinical management changes ranging 
from transition to palliative care for uniformly lethal conditions to alteration or initiation of 
medical or surgical therapy to improve outcomes in others. Thus, institution of 2-day WGS at time 
of acute presentation opens the possibility of early implementation of precision medicine. This 
implementation may create opportunities for early interventional therapies, which would 
frequently be novel or off-label, that may alter disease trajectory in infants with what would 
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otherwise be fatal disease. Widespread deployment of rapid WGS and precision medicine will 
raise ethical issues pertaining to interpretation of variants of unknown significance, discovery of 
incidental findings related to adult onset conditions and carrier status, and implementation of 
medical therapies for which little is known in terms of risks and benefits. Despite these challenges, 
precision neonatology has significant potential both to decrease infant mortality related to genetic 
diseases with onset in newborns and to facilitate parental decision-making regarding transition to 
palliative care.
Introduction
The completion of the first composite human genome sequence in April, 2003 marked the 
dawn of the promise of precision medicine – a new approach to medicine wherein diagnosis, 
treatment, and risk factor modification would be informed by an individual's unique genetic 
make-up. While mature models of precision medicine remain to be defined, changes in the 
speed and cost of whole genome sequencing (WGS) are bringing the details of initial 
applications into focus. NIH Director, Francis Collins, foresees a society in which every 
baby will have access to their sequenced genome in order to modify their strategies for 
disease prevention, detection and treatment[1]. In the 2015 State of the Union Address, 
President Barack Obama announced the creation of a precision medicine initiative, 
ultimately to provide each individual with personalized information to drive expedient 
diagnoses and individualized, more effective treatments. The transformation of healthcare 
through the use of personal WGS information has already begun in Neonatal Intensive Care 
Units (NICUs). Since 2011, neonatologists at our institution have, through research 
protocols, used research-based rapid WGS in acutely ill infants and their parents to diagnose 
the underlying genetic cause of the neonates’ conditions[2–4]. Furthermore, in a research 
setting, it is now possible to sequence human genomes at a cost of less than $1000 per 
individual. At this early stage in its evolution, we review the premise, practicality, and 
potential of rapid WGS for neonatal precision medicine.
Monogenic Diseases: Neonatal Impact and Incidence
Monogenic diseases are conditions causally related to genomic change(s), or variant(s), in a 
single gene. This collection of diseases is currently most amenable to diagnosis through 
WGS because the causative variants frequently involve one or a few contiguous DNA 
nucleotides in one or a handful of genes. These variants interfere with the efficient 
functioning of a gene product through disruption of transcription, translation, protein 
modification, complex assembly or function. They may be inherited from a parent or occur 
de novo as a mutation in the germ cell of one of the parents. It is estimated that each 
individual's germline genome harbors about 74 de novo single nucleotide variants [5–7]. 
When these de novo variants are associated with dominantly expressed phenotypes, they 
tend to present in the newborn period because they are often more deleterious than inherited 
variants due to the absence of evolutionary selection [8, 9].
As a proportion of overall disease burden, monogenic diseases decrease in importance with 
age, and their impact is highest in fetal, perinatal, and neonatal care respectively. The 
incidence of each individual monogenic disease is rare, but in toto, they are common. It is 
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estimated that 60 million people in the United States and Europe have rare genetic diseases, 
of which 75% are children. Of these 45 million children, an estimated 30% will die before 
the age of 5 years[10]. Genetic diseases and birth defects are the leading cause of infant 
death in the United States with many of these being monogenic[11]. While the proportion of 
newborns admitted to the NICU with genetic disorders is unknown, 76% of NICU patients 
are admitted for reasons other than prematurity[12, 13]. A 1991 study from Scotland 
determined, in a cohort of 821 consecutive admissions to the NICU, that 5.7% of the 
admissions were for chromosomal or monogenic disorders[14]. This is likely a considerable 
underestimate given lack of NGS at that time. Infants with recognizable genetic disorders 
have disproportionately longer hospitalizations and more frequent neonatal death[15–20].
At present, newborns and infants with congenital malformations, syndromes, and inherited 
disorders typically undergo an extensive diagnostic process, with relatively low rates of 
etiologic diagnosis[4]. It is suspected that 3% of babies born in the US and Europe will have 
a major birth defect, with only 10–20% of these having an identifiable syndrome[21]. Acute 
management decisions are therefore typically made in the absence of a definitive diagnosis, 
which leads to delays in initiation of effectual treatments or to the use of empiric treatments 
that are ineffective, have adverse effects, or exacerbate symptoms. Thus, the timely return of 
definitive diagnoses of monogenic diseases during a NICU stay can potentially result in 
substantive changes in practice for neonatologists and consulting subspecialists[4]. In 
addition to having the potential to modify medical treatment in amenable cases, rapid 
genetic diagnosis allows for rational refocusing of care to diminish neonatal suffering and to 
support familial grieving in futile situations. These end-of-life decisions are common in 
neonatal genetic diseases, with most deaths resulting from withholding or withdrawing 
care[22]. Given the limitations to parental bonding and contact with the baby in the NICU 
setting, earlier holistic, end-of-life care decisions shifts focus from invasive medical 
management to the alleviation of suffering, allowing the family to bond, say “goodbye,” 
baptize or give last rites, and facilitate the grieving process. Thus, early definitive diagnosis 
may actually increase neonatal (28-day) mortality in patients with genetic diseases, whilst 
having the potential to decrease infant (1 year) mortality.
Genetic diseases also have significant societal costs associated with profound emotional, 
financial, social, and physical stress within families[23, 24]. The impact of newborn genetic 
diseases and birth defects on family structure is profound with studies identifying increased 
maternal depression and anxiety. The presence of maternal anxiety and depression are 
associated with childhood behavioral, developmental, and persistent health 
complications[25]. In a 1997 report, parental divorce occurred in 50 % of families with a 
child with a genetic disease[26]. Rapid, precise diagnosis coupled with robust treatment and 
support teams may offset not just direct medical expense but larger familial and societal 
costs of genetic disease in infancy.
Rapid Whole Genome Sequencing Methods
While the specifics of rapid WGS will differ from institution to institution, we have reported 
on our three year experience of sequencing selected neonates and infants for diagnosis of 
likely genetic diseases[2–4] described briefly as follows. Enrollment of parental and 
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proband trios is preferred, and every effort is made to sequence both parents. After informed 
consent is obtained, the presenting clinical features are ascertained by review of electronic 
health records and translated into structured Human Phenotype Ontology terms[2, 27]. 
These terms are then mapped to the approximately 5430 known monogenic disorders and 
3353 genes using either an in-house clinicopathologic correlation tool, Symptom & Sign 
Assisted Genome Analysis (SSAGA), or publically available software, such as Phenomizer,
[2, 3, 28, 29] generating a rank ordered differential diagnosis of diseases and assocatied 
genes. DNA is isolated from participants and sequenced using an Illumina HiSeq 2500 in 
rapid mode. Short reads are computationailly aligned to the GRCh37 human reference 
genome, and variants identified with software, including short nucleotide substitutions, 
deletions, and insertions.[2–4, 30, 31].
Each individual sample sequence yields 4 to 5 million nucleotide variants that differ from 
the human reference genome. Through a variety of commercially available and in-house 
computer programs, each of these variants is genotyped and annotated[2]. The annotation 
process incorporates data from ENSEMBL Variant Effect Predictor software[32] comparing 
variants from the NCBI Single Nucleotide Polymorphism Database, Human Gene Mutation 
Database disease-causing variants[33, 34], and performing additional in silico prediction of 
variant consequences using RefSeq and ENSEMBL gene interpretations[35, 36]. Variants 
are categorized according to ACMG recommendations for reporting sequence variation[34, 
37] along with a minor allele frequency from our in-house database[2]. Variants are filtered 
using a minor allele frequency of <1% and ACMG categories 1–5 (With a focus on Cat 1–3 
known pathogenic, likely pathogenic, or unknown significance respectively). Analysis is 
further limited to variants in genes that ranked high in correspondence to the phenotype of 
the affected infant or child. If a single, likely-causative variant is identified for an autosomal 
recessive condition, the entire coding region is manually inspected using the Integrated 
Genomics Viewer[38]. Expert interpretation and literature curation are performed for all 
likely-causative variants with regard to evidence for pathogenicity[37]. Rapid WGS, from 
sample procurement to test result, can be completed in less than 50 hours[2]. Currently, all 
causative variants identified by WGS are confirmed by Sanger sequencing prior to clinical 
reporting. If the subject's phenotype differs from those previously reported for mutations in 
the suspected disease gene, additional expert consultation and functional confirmation is 
performed. We do not currently report variants of unknown significance, carrier status, or 
predisposition for adult onset diseases. Reports in the health record are limited to confirmed 
variants that explain the presenting phenotype of the infant.
Experience with Whole Genome Sequencing in Neonates
Our early experience with rapid WGS involved 35 acutely ill infants whose genomes were 
sequenced with their families as parent-child trios[4]. All infants were less than 4 months of 
age at time of enrollment, had a suspected genetic cause of their symptoms, and lacked a 
molecular or genetic diagnosis. The infants enrolled for sequencing had diverse 
presentations, with symptoms typically apparent at birth (Table 1) and received multiple 
standard genetic tests in addition to WGS. In this highly selected group of NICU infants, 
rapid WGS provided a genetic diagnosis in 20 patients (57%), in contrast to only 9% 
diagnostic rate with standard genetic testing in the same individuals. Sanger sequencing 
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confirmed 100% of WGS diagnostic findings. In all cases examined, WGS analysis also 
identified variants of unknown significance that did not explain the etiology of illness or 
lacked sufficient evidence of pathogenicity and were not reported. The significance of these 
variants may change as more information is acquired on the role and functions of these 
genes and variants.
No presenting symptoms seemed to confer a higher diagnostic rate with WGS (Table 1). 
Recurrent genes with causative variants were PTPN11 (Noonan/LEPOARD syndrome), 
CHD7 (CHARGE syndrome), and SCN2A (Early infantile epileptic encephalopathy). 
Dominant de novo mutations were the most commonly found mechanism of disease variant 
accrual (65%). The recognition of de novo and somatic mutations as common causes of 
neonatal genetic diseases was important since family history is negative in such situations 
and the disease appears to be sporadic in origin. WGS of parent – infant trios is critical for 
recognition of de novo variants as the absense of the variant in the unaffected parents lends 
strong indirect support to the pathogenicity of the variant identified in the patient. WGS also 
provides good coverage of the mitochondrial genome and yielded one maternally-inherited 
diagnosis in the 35 cases. Of five patients with autosomal recessive inheritance, four had 
compound heterozygous variants, and one, from a genetically isolated population, had a 
homozygous causative variant. This mix of inheritance patterns is similar to that seen in 
recently published large case series of exome and genome sequencing (Table 2).
Among infants receiving WGS diagnoses, the degree of overlap between the classical 
clinical features of the disease and the presenting symptoms of the infants was frequently 
modest. Of the 20 infants receiving a diagnosis by WGS, 9 (45%) were conditions that had 
not been considered in the differential diagnosis at the time of enrollment. These infants 
either had yet to develop the classical disease presentations (i.e. to “grow into their 
phenotype”) or represented unappreciated disease pleiotropy. Prior to WGS, there has not 
been a generalizable method for genetic disease diagnosis in newborns, and it is anticipated 
that our current knowledge of newborn presentations of genetic diseases may represent the 
tip of the phenotypic iceberg. In two of 35 cases, the genetic disease was novel and 
previously unpublished. It was encouraging in these situations that rapid WGS, nevertheless, 
yielded diagnoses. However, as noted above, there is probably yet an under-diagnosis of 
genetic diseases in infants with variants of unknown significance with our methods that will 
be clarified with time. There likely are many more novel genetic diseases that present as 
stillbirths or as extreme presentations of otherwise normal neonatal illness.
For this preliminary data, the average age at enrollment for WGS was 26 days, with the 
median time to confirmed, reported diagnosis of 23 days. Median time from enrollment to 
WGS analysis was 5 days, with interpretation and Sanger confirmation taking the remaining 
time to report clinically. Of the 35 infants in this initial experience, the median NICU or 
PICU stay was 42 days with a range of 3 – 387 days. 120-day mortality was 40% overall (14 
of 35) but higher in those with a genetic diagnosis identified by WGS (55%, 11 of 20). 
These data indicate limitations of rapid WGS at present. First, the window for possible 
intervention is small when one accounts for the delay in enrollment coupled with the 
significant early mortality in the patients with genetic diagnoses. Additionally, if an infant is 
acutely ill due to an early presentation of an inborn error of metabolism, the turn-around 
Petrikin et al. Page 5













time for basic biochemical testing is still more rapid than rapid WGS. WGS complements 
but does not replace conventional tandem mass spectrometry (MS/MS) newborn screening. 
Where a singular genetic disease diagnosis is likely, and if conventional molecular testing 
can be performed in-house, rapid WGS is unlikely to be superior due to current research 
restrictions and required Sanger confirmation which currently adds nearly a week to return 
of results.
Clinical Outcomes and Impact of Genomic Diagnoses
The clinical impact of WGS testing was positive in 65% of diagnoses according to clinician 
report. Specific services enabled by these rapid genetic diagnoses included institution of 
palliative care, initiation of new subspecialist consultant, or change in medication, diet, 
imaging study, surgical procedure, or specific genetic counseling. Of the 13 diagnoses made 
prior to discharge or death, 11 (85%) were considered to have acute clinical utility. 
Palliative care was instituted more often in infants receiving a genetic diagnoses than those 
who did not (6 of 20, 30%, versus 0 of 15, respectively).
Two Illustrative Cases of Clinical Impact
Of the previously published cases, two are presented as illustrations of potential clinical 
impact[4]. The first, CMH487, was admitted to the NICU at birth with multiple congenital 
anomalies. He developed acute hepatic failure on day of life (DOL) 56. Intravenous 
corticosteroids and immunoglobulin were started empirically on DOL 67 and 69, 
respectively. The infant-parent trio was enrolled on DOL 71. Rapid WGS gave a provisional 
molecular diagnosis of hemophagocytic lymphohistiocytosis. Since this diagnosis was 
actionable and the infant was at imminent risk of death, the provisional molecular diagnosis 
was reported verbally on DOL 74, before confirmatory testing. Subsequently, this diagnosis 
was confirmed by Sanger sequencing, and formally reported on DOL 77. The diagnosis was 
further solidified by functional studies on NK cells. On DOL 81, the knowledge of the 
genetic diagnosis allowed institution of published treatment protocols for this patient with 
discontinuation of extraneous and potentially harmful empiric therapies. The patient had 
resolution of coagulopathy by DOL 88. At 24 months of age, the child has normal liver 
function.
CMH569 was admitted to the PICU on DOL 34 with a blood glucose of 18 mg/dL. 
Hypoglycemia was refractory to glucose infusion and diazoxide. Hyperinsulinemia was 
detected. The infant-parent trio received rapid WGS on day of life 41. A provisional 
molecular diagnosis of type 1 familial hyperinsulinism was reported on DOL 45. 
Furthermore, rapid WGS suggested the disease to be focal (adenomatous hyperplasia that 
involved only part of the pancreas). The Sanger-sequence confirmed diagnosis was reported 
on DOL 50. Functional imaging confirmed focal pancreatic lesions, allowing targeted partial 
pancreatectomy instead of the previously planned total pancreatectomy which would have 
led to life long brittle diabetes mellitus. Rapid WGS shortened the PICU stay by 
approximately three weeks, as well as the morbidity associated with breakthrough 
hypoglycemia. At 17 months of age, the patient is euglycemic without need for insulin 
therapy.
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Using our baseline three year experience with rapid WGS of selected neonates and infants 
for diagnosis of likely genetic diseases, we developed a prospective study of the diagnostic, 
clinical, and psychosocial utility of rapid WGS in the NICU (ClinicalTrials.gov Identifier: 
NCT02225522). This study is part of a multicenter investigation funded by the NIH under 
the Newborn Sequencing In Genomic medicine and public HealTh (NSIGHT) collaborative 
which seeks to explore the implications, challenges, and opportunities associated with the 
use of genomic sequence information in the newborn period.
At our site, we are understaking a prospective, random blinded study of the utility of rapid 
WGS in the care of ill neonates. Potentially eligible newborns are nominated for the study 
by neonatologists in our level IV NICU, which has an annual census of approximately 900 
neonates. Inclusion criteria for enrollment require that either a genetic test or genetic 
subspecialty consult has been ordered, a major congenital anomaly or multiple minor defects 
is present, or a poor response to routine care for a condition is identified (raising the 
suspicion of an underlying genetic etiology). Exclusion criteria include infants > 4 months 
of age, features pathognomonic for a known chromosomal anomaly, or a confirmed 
molecular genetic diagnosis. Upon acceptance of nominations, informed consent from both 
parents is obtained prior to participation as required by the IRB. Efforts are made to enroll 
and sequence the proband and both parents when possible. To date, timely nomination (i.e. 
within days of life 0–5) has proven difficult; the rates of nomination vary widely by 
neonatologist (from 0 – 10%) and consent is obtained in ~50% of accepted nominations. 
Major reasons for failure to obtain consent are the unavailability of a second parent, 
underage parents, mothers who do not wish the father contacted, and unwillingness to 
undergo WGS (primary stated reason is related to perceived limitations of the Genetic 
Information Nondiscrimination Act of 2008). Enrolled infants and family members then 
undergo sequencing and variant identification as described above.
Current Limitations
Rapid WGS is a quickly evolving technology that still has multiple limitations. Causative 
larger, structural variants that affect single loci are sought using computational tools, but 
these methods currently lack sufficient sensitivity and specificity for clinical use. The short 
sequences generated in rapid WGS preclude their use for diagnosis of triplet repeat 
expansion disorders and in some disease genes with nonfunctional but highly homologous 
intronic regions called pseudogenes. Sequencing advances will likely be able to address 
these limitations in the near future. A much more difficult hurdle in rapid WGS application 
involves interpretation of variant pathogenicity. That is, determining if the variant both 
effects the gene function, and if that effect reasonably may be causing the patient’s 
symptoms. Each patient has many variants that are unique or private to them and 
determination of whether the variant may be pathogenic may be inferred from various 
sources, including similar changes that have been reported or in silico analysis of the 
importance of the variant. However, determining variant causality in the absence of prior 
literature involves functional testing. This method of testing for each variant, while 
compelling, is expensive and labor intensive.
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Outside of variants of unknown significance, there are technologic limitations of rapid WGS 
that need to be understood. False positive results are variants labeled in the literature as 
pathogenic or predicted to be pathogenic by software tools that are actually not disease 
causing. The “over-interpretation” of variant pathogenicity was an even greater problem 
prior to WGS or exome sequencing, when only a few candidate genes were sequenced. At 
this early phase of precision medicine, some false positive errors due to erroneous medical 
literature are unavoidable and may become more common as testing moves to wider groups 
of newborns with lower pre-test probability of genetic disease. In one sense, even with 
Sanger technical confirmation, these diagnoses remain provisional until either enough 
literature is accumulated to confirm that association, the child develops a full phenotypic 
manifestation of disease, or orthogonal functional testing is performed. The ACMG has 
recently issued detailed guidelines for structured methods for evaluating the evidence in 
support of a variant being disease causing[37]; however, the adoption of these new 
guidelines is time consuming and necessitates highly expert laboratory directors.
There will also inevitably be false negative results with expanded use of WGS. These can 
occur from missing variant calls, miscategorization of variants in introns, untranslated 
regions and regulatory elements as “silent”, or from inherent insensitivity of WGS for 
detection of structural variants. The most common form of false negative, though, likely 
comes from undiscovered disease genes, changes in deep intronic regions that affect gene 
expression, and incomplete knowledge of the spectrum of clinical presentations of known 
disease genes. At present there are more than twenty novel disease gene discoveries or 
substantive phenotype expansions reported each month. As our knowledge of gene function, 
network function and regulatory mechanisms grow, these gaps in diagnosis will diminish. 
An additional source of error is identification of the wrong pattern of inheritance, which can 
lead to erroneous genetic counseling. One example is under-reporting of de novo variants, 
which have extremely low likelihood of recurrence. These difficulties with variant 
interpretation are the basis from which many ethical arguments arise.
Ethics of Widespread Genome Sequencing
The prospect of WGS of infants is forcing society to grapple with ethical issues such as the 
child’s right to an open future, a family's right to know about health predispositions, the 
nature of informed consent, and returning of results related to adult onset diseases or risk 
factors of conditions not manifesting during infancy and/or childhood. Much literature exists 
related to the issue of return of secondary (or incidental) genetic variant findings, but 
without coalescence to a consensus. Initially, the ACMG had suggested that all genomic 
sequencing tests should report incidental findings on 56 disease genes for which treatments 
are available, irrespective of the reason for the sequencing. This has now been modified with 
a position statement allowing parents and patients to opt out of receiving this information. 
The original position statement raised concerns about engendering anxiety within the 
families of our patients and impinging on the right of pediatric patients to be free from the 
burden of predisposition to adult onset diseases. This "Right to an Open Future" informed 
our current practice of restricting our search for disease-causing variants to changes in genes 
with some reported relationship to the presenting symptoms. As mentioned above, many of 
our patients with rapid WGS diagnoses had not yet fully manifested the classical symptoms 
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of their diagnosis, so this approach may be overly restrictive. However, through discussion 
with our pediatric bioethics center, filtering our examination of variants by the patient's 
presenting symptoms was deemed to be the best compromise between increasing sensitivity 
of diagnosis and protecting the child's rights. Specifically, if we do not review the variants 
for breast cancer or Alzheimer disease, then we cannot report this information. Even in the 
analysis of relevant variants, though, finding some variants with impact on adult onset 
conditions is inevitable. Our solution to addressing these issues is to not to return any results 
clinically that do not directly impact on the nominating symptoms. Parents are informed of 
this policy prior to obtaining consent. These measures provide some guidance for returning 
results, but ethical issues associated with testing are still present. For these unforeseen cases, 
we turn to advice from our colleagues in pediatric bioethics to help guide decision making.
Future Implications for Precision Medicine
The evidence to date, while retrospective, strongly suggests that rapid WGS does have 
utility for timely genetic disease diagnosis for ill NICU infants, even before a fully 
developed symptom complex evolves. However, prospective evidence has not yet been 
published. A goal of the Children’s Mercy NSIGHT study is to prospectively assess the 
diagnostic yield of rapid WGS with that of standard genetic testing in a randomized, 
controlled study. We seek to also address important questions of which diseases and 
presentations rapid WGS does or does not have diagnostic effectiveness, those in which 
diagnoses change acute medical management, and whether there are potential harms of rapid 
WGS in the NICU. The provision of a diagnosis frequently holds power for a family 
regardless of the impact on clinical management. Families speak of ‘not having to search 
anymore,’ of ‘being able to give a name to the disease,’ and feel like they can ‘stop looking.’ 
With increased connectedness, this also allows families of children with rare diseases to find 
support from others with the same or similar diagnosis, even when separated by great 
distances. Thus, rapid WGS is also anticipated enable personalized genetic counseling and, 
in some cases, allow a more natural death with retraction of medical technology that 
separates the parents and child. This study will further allow the collection of multiple use 
cases, from which initial answers to these questions can be informed. In particular, there is a 
great need to define processes for clear communication of genetic disease diagnoses with 
counseling and support to help parents to process this information and navigate their options 
for their babies who will have a future of major morbidity from a genetic disease. While a 
diagnosis alone is impactful for families, the great hope for rapid WGS-based diagnoses is 
that earlier instigation of precise, effective care – before irreversible organ damage or 
disease progression – will result in change in care and improved clinical outcomes in a 
subset of infants (Box 1, Figure 1). While that subset may be small today, the ability to 
make a timely diagnosis may render some genetic diseases tractable from a pharmaceutical 
development standpoint[39]. Currently, for many genetic diseases of newborn onset there is 
not an evidenced-based therapeutic literature. These diseases are individually very rare, thus, 
precluding adequate power for standard randomized trial designs of investigational new 
treatments (INDs) that compare multiple strategies for optimal efficacy[39]. Newborn-onset 
genetic diseases also frequently have rapid progression – 120-day mortality was more than 
50% in our case series[4]. This rapid progression, when combined with delayed molecular 
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diagnosis, negates any window for consideration or implementation of INDs. Rapid WGS 
has the potential to alter this dynamic by efficiently identifying diagnoses that are so rare as 
to be without accepted treatments thereby creating the time interval needed to define and 
implement a modified N-of-1 therapeutic study guided by the effected biological pathway 
involving currently unproven treatments[39]. Such N-of-1 studies would identify novel 
therapeutic approaches by examination of the mechanism whereby a mutated gene causes 
pathophysiology through literature review, seeking molecular opportunities to intervene, and 
evaluating other genes for which drugs have been developed with which the disease gene 
product may interact to cause pathophysiology[39]. N-of-1 studies would also be based on 
the premise of case reports of prior novel therapeutic interventions in that specific disease, 
which, although not rising to the status of a proven treatment, merit additional study. 
Currently approved medications (which are likely to be off-label for these very rare 
conditions) and/or dietary supplements could then be repurposed in the setting of a 
structured, IRB-approved, N-of-1 study, with defined end-points, surrogate biochemical 
effect markers, and dose escalation[39].
For example, Kabuki syndrome is a rare genetic disease characterized by typical facial, 
minor skeletal anomalies, intellectual disability, and growth deficiency. Patients with 
Kabuki syndrome frequently have increased susceptibility to infections and autoimmune 
disorders, seizures, endocrine abnormalities, feeding problems, and deafness[40]. Kabuki 
syndrome is caused by heterozygous mutation in KMT2D or KDM6A. The FDA approved 
antibiotic, gentamicin, can induce read-through of nonsense codons that result in 
haploinsufficiency of KMT2D and KDM6A in cell lines derived from patients with Kabuki 
syndrome[41]. Thus, an N-of-1 study of gentamicin[42, 43] in Kabuki syndrome could 
potentially be designed, in which the expression of KMT2D target genes and post-natal 
growth were employed as a surrogate markers of treatment effect[41]. Markers of potential 
adverse effects of nephrotoxicity and ototoxicity would also require careful monitoring in 
the case of gentamicin use.
Through the development of a culture of N-of-1 studies of genetic diseases in the NICU, a 
knowledge base of treatments of rare diseases can eventually be built. It should be noted that 
many genes act through common biochemical pathways, so evidence generated in one 
genetic disease may support the use of a treatment in another, guided by an understanding of 
gene pathways.
In this protected population, precision neonatology must avoid heroic efforts that prolong 
suffering without the promise of significant therapeutic benefit. Guiding these measures 
must be respect for the infant and family, with benefits maximized, and risks must be 
reasonable and minimized. Parents must be informed of the experimental nature of such 
trials and only non-exploitative procedures should be used. The challenge going forward 
will be to develop teams and practices that can respond to rapid genetic diagnosis with 
specific interventions and treatments, including pharmacologic interventions, pulling from 
multispecialty teams that will realize the promise of precision medicine[39].
In cases where diagnosis leads to either palliation or effective treatments, rapid WGS is 
anticipated to shorten hospital stays, reduce empiric treatments, and simplify the diagnostic 
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work-up increasing the cost-effectiveness of rapid genomic analysis. There are multiple 
current formats for WGS at present and an acuity guided strategy seems most appropriate at 
present, where rapid WGS is reserved for acutely ill infants in whom a diagnosis may be 
genetic. Exome sequencing, for example, costs about one third that of standard WGS but 
incurs about one day of additional turnaround time. Standard WGS takes approximately 5 
days of additional turnaround time. Two day WGS is about three to four times more 
expensive than standard WGS. Even faster formats are now possible. We can now 
reproducibly perform WGS and analysis in ~30 hours, and strategies have been described 
that can reduce this to less than 20 hours[44]. From a practical standpoint, the greatest 
benefit is likely if rapid WGS is instituted within the first day of life and completed within 2 
days (Figure 2). As noted above, average age at NICU enrollment was 23 days[4], somewhat 
blunting the current impact of diagnosis and certainly arguing that a standard WGS or 
exome protocol would provide comparable results in most cases.
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Precision Medical Management following rapid genetic disease diagnosis 
in the NICU
1 Psychosocial benefits for parents (answers, knowledge of prognosis, 
planning, psychological and religious support).
2 Precision treatments for affected infants that prevent death, diminish disease 
severity, delay progression or improve quality of life.
4 Earlier avoidance of futile or painful treatments, unnecessary or invasive 
testing, and planning of withdrawal of care.
5 Time to plan and implement investigative new treatments.
6 Basis for increased coordination of care among providers.
7 Genetic counseling regarding recurrence risk.
8 Parental referral to specific support groups.
9 Reduced lifetime cost of care.
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Actual and desired 120-day mortality of NICU infants receiving rapid genetic disease 
diagnoses. In suffering neonates with hopeless diagnoses, rapid diagnosis will allow planned 
withdrawal of support in a more timely manner. Precision medicine interventions in 
remaining infants are anticipated to reduce infant mortality.
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Actual and desired time to genetic disease diagnosis by rapid WGS (STATseq). Ideally, 
blood samples would be obtained at birth and diagnoses would be returned by DOL 2 to 
optimize provision of precision medicine.
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Table 1
Clinical findings in 20 infants who received genetic disease diagnoses by rapid WGS.
Demographics Value
Symptom onset (Average, range, days) 0.5 (0–7)
Multisystem Congenital Anomalies 5 (25%)
Neurologic findings 4 (20%)
Cardiac findings/Heterotaxy 3 (15%)
Hydrops/Pleural Effusion 2 (10%)




Hepatic findings 1 (5%)
Dermatologic findings 1 (5%)
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